These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 14700015)

  • 1. Safety and tolerability of atypical antipsychotics in patients with bipolar disorder: prevalence, monitoring and management.
    Chue P; Kovacs CS
    Bipolar Disord; 2003; 5 Suppl 2():62-79. PubMed ID: 14700015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder.
    McIntyre RS; Konarski JZ
    J Clin Psychiatry; 2005; 66 Suppl 3():28-36. PubMed ID: 15762832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Metabolic side effects of risperidone in early onset schizophrenia].
    Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
    Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolactin-related and metabolic adverse effects of atypical antipsychotic agents.
    Henderson DC; Doraiswamy PM
    J Clin Psychiatry; 2008; 69 Suppl 1():32-44. PubMed ID: 18484806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia.
    Keck PE; McElroy SL; Strakowski SM; Soutullo CA
    J Clin Psychiatry; 2000; 61 Suppl 4():33-8. PubMed ID: 10739329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.
    Newcomer JW
    CNS Drugs; 2005; 19 Suppl 1():1-93. PubMed ID: 15998156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of real-world data on the effects of aripiprazole on weight and metabolic outcomes in adults.
    Citrome L; Kalsekar I; Baker RA; Hebden T
    Curr Med Res Opin; 2014 Aug; 30(8):1629-41. PubMed ID: 24666104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atypical antipsychotic tolerability and switching strategies in bipolar disorder.
    Liauw SS; McIntyre RS
    Expert Opin Pharmacother; 2010 Dec; 11(17):2827-37. PubMed ID: 20726821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Managing the side effects associated with commonly used treatments for bipolar depression.
    Kemp DE
    J Affect Disord; 2014 Dec; 169 Suppl 1():S34-44. PubMed ID: 25533913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Schizophrenia, diabetes mellitus and antipsychotics].
    Gury C
    Encephale; 2004; 30(4):382-91. PubMed ID: 15538314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of atypical antipsychotic drugs versus conventional medication in schizophrenia.
    Luft B; Taylor D
    Expert Opin Pharmacother; 2006 Sep; 7(13):1739-48. PubMed ID: 16925501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives.
    Baptista T; Kin NM; Beaulieu S; de Baptista EA
    Pharmacopsychiatry; 2002 Nov; 35(6):205-19. PubMed ID: 12518268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The metabolic syndrome and antipsychotics in children and adolescents].
    Dori N; Green T
    Harefuah; 2011 Oct; 150(10):791-6, 814, 813. PubMed ID: 22111125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolerability of atypical antipsychotics.
    Stanniland C; Taylor D
    Drug Saf; 2000 Mar; 22(3):195-214. PubMed ID: 10738844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perceptions of weight gain and bipolar pharmacotherapy: results of a 2005 survey of physicians in clinical practice.
    Ketter TA; Haupt DW
    Curr Med Res Opin; 2006 Dec; 22(12):2345-53. PubMed ID: 17257449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme.
    Poulin MJ; Chaput JP; Simard V; Vincent P; Bernier J; Gauthier Y; Lanctôt G; Saindon J; Vincent A; Gagnon S; Tremblay A
    Aust N Z J Psychiatry; 2007 Dec; 41(12):980-9. PubMed ID: 17999270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents.
    Toren P; Ratner S; Laor N; Weizman A
    Drug Saf; 2004; 27(14):1135-56. PubMed ID: 15554747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experimental antipsychotics and metabolic adverse effects--findings from clinical trials.
    Tschoner A; Fleischhacker WW; Ebenbichler CF
    Curr Opin Investig Drugs; 2009 Oct; 10(10):1041-8. PubMed ID: 19777392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic and endocrine disturbances in psychiatric disorders: a multidisciplinary approach to appropriate atypical antipsychotic utilization.
    Masand PS; Culpepper L; Henderson D; Lee S; Littrell K; Newcomer JW; Rasgon N
    CNS Spectr; 2005 Oct; 10(10):suppl14 1-15. PubMed ID: 16404802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.